

Triptodur[®] LA

(triptorelin extended release suspension)

When requesting Triptodur[®] LA (triptorelin extended release), the individual requiring treatment must be diagnosed with the following FDA-approved indication and meet the specific coverage guidelines.

FDA-approved indication(s)

Triptodur LA[®] (triptorelin) is indicated for the treatment of central precocious puberty.

Coverage Guidelines

The individual meets the following criteria for approval:

- 1) Has the diagnosis of central precocious puberty.

The individual meets the following criteria for extended approval:

- 1) Dependent on many factors, including the age of the child, bone age, target height, growth velocity, and social desire to have pubertal progression concurrent with the child's peers.

Approval duration: 12 months

Recommended dosing

22.5mg injection IM every 24 weeks.

References

1. Triptodur[™] [prescribing information]. Atlanta, GA: Arbor Pharmaceuticals, LLC; September 2017.
2. Harrington J, Palmert MR. Treatment of precocious puberty. Available at: uptodate.com. Updated September 26, 2017. Accessed on September 7, 2018.
3. Carel JC, Eugster EA, Rogol A, et al. Consensus statement on the use of gonadotropin-releasing hormone analogs in children. *Pediatrics*. 2009 Apr;123(4):e752-62.